Taking advantage of our in-house experimental data on 3-cyano-2-imino-1, 2-dihydropyridine and 3-cyano-2-oxo-1,2-dihydropyridine derivatives as inhibitors of the growth of the human HT-29 colon adenocarcinoma tumor cell line, we have successfully developed CoMFA and CoMSIA models. These models yielded highly significant cross-validations (CoMFA: q2cv= 0.70; CoMSIA: q2cv= 0.639) and excellent predictions of a 5 ligand test set (r2pred between 0.61 and 0.65). Exploiting this information, synthesis and experimental data directed us to the synthesis of two novel cell growth inhibitory agents with IC50s in the submicromolar range.
